EUVIMEDAtklāt EUVIMED
CrossrefInformācijas karte

Role of Progesterone and Inhibin A in Predicting the Adverse Outcome of Pregnancy

Ahmed Hassan Khedr, Amany Seif Mohammed Soliman, Yasmine M. Amrousy, Shaimaa Elsayed Belal

Journal of Medicine in Scientific Research · 2024-01-01 · 7 (2)

DOI: 10.59299/2537-0928.1072 ↗
AbstraktsBibliogrāfiskie dati

Abstrakts

Background: The prediction of future miscarriages in patients who have had a first-trimester abortion can be improved by measuring levels of inhibin A and progesterone. Pregnancy outcomes can be improved by using this important information to direct clinical treatment and care Objective. Progesterone and Inhibin A during the first trimester can be used to quickly and precisely detect pregnancy outcomes, improving prenatal services. Methods: A total of 180 women from Badr City Hospital participated in the study, split up into two groups: group b contained ninety women who had undergone a first-trimester abortion, and group a comprised ninety well-being expectant mothers. The cases was carefully evaluated by comprehensive medical history, cervical-pelvic examinations, and transvaginal ultrasound. Enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of progesterone and inhibin A in blood samples. The goal of the study was to compare the two groups' hormone levels. Results: The findings of the study indicate that low progesterone levels, high diastolic blood pressure, previous abortions, and primigravida may independently contribute to the risk of abortion with odds ratios (95% confidence intervals) , 0.895 (0.850-0.943), 1.123 (1.018-1.240), 26.857 (8.769-82.250) respectively, with associated p-values of

Jūsu darbam piemērotas zināšanas.

No bezmaksas sākuma un personīgās literatūras meklēšanas līdz pilnam Research Suite.

Skatīt tarifus →

Vai ir iekļauti visi izdevēju pilnteksti?

Nē. Bibliogrāfiskie ieraksti, kopsavilkumi un pilnteksti ir atšķirīgs saturs. Tas, vai pilnteksts ir pieejams, ir atkarīgs no avota, Open Access un jūsu esošajām licencēm. EUVIMED tarifs neaizstāj papildu izdevēju tiesības.

Skatīt tarifus →